keyword
MENU ▼
Read by QxMD icon Read
search

Chronic myeloid leukemia

keyword
https://www.readbyqxmd.com/read/29052661/adherence-and-coping-strategies-in-outpatients-with-chronic-myeloid-leukemia-receiving-oral-tyrosine-kinase-inhibitors
#1
Jochen Hefner, Eva-Johanna Csef, Volker Kunzmann
PURPOSE/OBJECTIVES: To assess adherence and coping strategies in outpatients with chronic myeloid leukemia (CML) on oral tyrosine kinase inhibitors (TKIs).
. DESIGN: Prospective, descriptive.
. SETTING: An interdisciplinary oncology outpatient clinic in Germany.
. SAMPLE: 35 outpatients with CML on oral TKIs.
. METHODS: Adherence and coping strategies were assessed with questionnaires. Clinical data were extracted from medical charts...
November 1, 2017: Oncology Nursing Forum
https://www.readbyqxmd.com/read/29051802/radotinib-and-its-clinical-potential-in-chronic-phase-chronic-myeloid-leukemia-patients-an-update
#2
REVIEW
Ahmet Emre Eskazan, Dilek Keskin
Although imatinib has dramatically improved major outcomes in patients with chronic myeloid leukemia (CML), there are newer tyrosine kinase inhibitors (TKIs) approved worldwide for the treatment of resistant cases, and two second-generation TKIs (dasatinib, nilotinib) are approved in some nations for treating patients in the upfront setting. Radotinib (IY5511HCL, Supect®) is a novel and selective second-generation BCR-ABL1 TKI, which is currently approved in Korea for the treatment of patients with CML both in the upfront and salvage settings...
September 2017: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29050203/loss-of-egr1-a-human-del5q-gene-accelerates-bcr-abl-driven-chronic-myelogenous-leukemia
#3
Silvia Maifrede, Andrew Magimaidas, Xiaojin Sha, Kaushiki Mukherjee, Dan A Liebermann, Barbara Hoffman
There is substantial evidence that early growth response-1 (Egr1) gene, a zinc-finger transcription factor, behaves as a tumor suppressor in leukemia. This includes reports from this laboratory that constitutive Egr1 overrides leukemia conferred by deregulated c-Myc or E2F-1 in the M1 myeloid leukemic cell line by promoting differentiation. To investigate the effect of Egr1 on the initiation and progression of Chronic Myelogenous Leukemia (CML), lethally irradiated syngeneic wild type mice were reconstituted with bone marrow (BM) from either wild type or Egr1 null mice transduced with a 210-kD BCR-ABL-expressing MSCV-retrovirus (bone marrow transplantation {BMT})...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29049187/a-myeloid-sarcoma-involving-the-small-intestine-kidneys-mesentery-and-mesenteric-lymph-nodes-a-case-report-and-literature-review
#4
Ping Wang, Quan Li, Li Zhang, Hong Ji, Cheng-Zhou Zhang, Bin Wang
RATIONALE: Myeloid sarcomas (MSs) are rare malignant hematological tumors. They most commonly occur in patients with acute or chronic myeloid leukemia. A de novo MS with no evidence of blood system disease is rare, but may represent the first sign of a systemic illness that precedes a full-blown disease. Herein, we report the computed tomography (CT) findings of an extremely rare case of a nonleukemic MS that progressed to acute myelogenous leukemia (AML) and simultaneously involved the small intestine, kidneys, mesentery, and mesenteric lymph nodes...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29046997/membrane-perturbation-through-novel-cell-penetrating-peptides-influences-intracellular-accumulation-of-imatinib-mesylate-in-cml-cells
#5
Devdeep Mukherjee, Niloy Kundu, Lopamudra Chakravarty, Birendra Behera, Prantar Chakrabarti, Nilmoni Sarkar, Tapas Kumar Maiti
Chronic myeloid leukemia is a stem cell disease with the presence of Philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22. The use of first- and second-generation tyrosine kinase inhibitors has been successful to an extent. However, resistance against such drugs is an emerging problem. Apart from several drug-resistant mechanisms, drug influx/efflux ratio appears to be one of the key determinants of therapeutic outcomes. In addition, intracellular accumulation of drug critically depends on cell membrane fluidity and lipid raft dynamics...
October 18, 2017: Cell Biology and Toxicology
https://www.readbyqxmd.com/read/29044676/world-health-organization-defined-eosinophilic-disorders-2017-update-on-diagnosis-risk-stratification-and-management
#6
Jason Gotlib
DISEASE OVERVIEW: The eosinophilias encompass a broad range of nonhematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end-organ damage. DIAGNOSIS: Hypereosinophilia has generally been defined as a peripheral blood eosinophil count greater than 1500/mm(3) and may be associated with tissue damage. After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of morphologic review of the blood and marrow, standard cytogenetics, fluorescent in situ-hybridization, flow immunocytometry, and T-cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic myeloid or lymphoproliferative disorder...
November 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29043239/a-case-of-synchronous-multiple-myeloma-and-chronic-myeloid-leukemia
#7
Ji-Young Lee, Sang-Min Lee, Hye-Kyoung Yoon, Ki-Hyang Kim, Moon-Young Choi, Won-Sik Lee
No abstract text is available yet for this article.
September 2017: Blood Research
https://www.readbyqxmd.com/read/29036785/wide-transcriptome-analysis-and-cellularity-of-bone-marrow-cd34-lin-cells-of-patients-with-chronic-phase-chronic-myeloid-leukemia-at-diagnosis-vs-12-months-of-first-line-nilotinib-treatment
#8
Alessandra Trojani, Ester Pungolino, Giuseppe Rossi, Mariella D'Adda, Milena Lodola, Barbara Di Camillo, Alessandra Perego, Mauro Turrini, Ester Orlandi, Lorenza Borin, Alessandra Iurlo, Simona Malato, Francesco Spina, Maria Luisa Latargia, Francesco Lanza, Salvatore Artale, Michela Anghilieri, Maria Cristina Carraro, Gabriella De Canal, Enrica Morra, Roberto Cairoli
BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined. OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions...
September 29, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29035454/the-relationship-between-mdm2-t309g-polymorphism-and-leukemia-in-the-chinese-population-evidence-from-a-meta-analysis
#9
Dewan Zhao, Ting Liu
BACKGROUND: Increasing numbers of studies have been carried out on the association of MDM2 T309G polymorphism with susceptibility to leukemia and have generated conflicting results. This meta-analysis updated and revaluated the possible associations between MDM2 T309G polymorphism and leukemia in the Chinese population. METHODS: The PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure, and Chinese Biology Medicine were searched up to February 2017...
October 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/29033820/pachyderma-in-primary-cutaneous-nk-and-t-cell-lymphoma-and-leukemia-cutis
#10
Eve Lebas, Cesar Chian, Nazli Nikkels-Tassoudji, Jorge E Arrese, Arjen F Nikkels
BACKGROUND: Pachyderma is defined as severely thickened skin with deep folds and is occasionally observed with primary cutaneous NK and T-cell lymphoma (pCNKTCL), primary cutaneous B-cell lymphoma (pCBCL), and leukemia cutis (LC). AIM: To describe the clinical, histological, and therapeutic particularities of a series of pCNKTCL, pCBCL, and LC patients with pachyderma. RESULTS: In a series of pCNKTCL (n = 70), pCBCL (n = 12), and LC (n = 2) patients followed up during 9 years, 6 cases of pachyderma were observed...
September 2017: Case Reports in Dermatology
https://www.readbyqxmd.com/read/29033451/dasatinib-and-azacitidine-followed-by-haploidentical-stem-cell-transplant-for-chronic-myeloid-leukemia-with-evolving-myelodysplasia-a-case-report-and-review-of-treatment-options
#11
Fabian Lang, Lydia Wunderle, Heike Pfeifer, Susanne Schnittger, Gesine Bug, Oliver G Ottmann
BACKGROUND CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging. The prognostic significance of these genetic findings is uncertain, even as singular aberrations, with nearly no data on management and outcome when they coexist. MDS evolving during the course of CML may be either treatment-associated or an independently coexisting disease, and is generally considered to have an inferior prognosis...
October 16, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29033428/the-efficacy-of-reduced-dose-dasatinib-as-a-subsequent-therapy-in-patients-with-chronic-myeloid-leukemia-in-the-chronic-phase-the-ld-cml-study-of-the-kanto-cml-study-group
#12
Noriyoshi Iriyama, Ohashi Kazuteru, Satoshi Hashino, Shinya Kimura, Chiaki Nakaseko, Hina Takano, Masayuki Hino, Michihiro Uchiyama, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi
Objective The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily). Methods Patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were being treated with low-dose imatinib (≤200 mg/day), but were resistant to this agent were enrolled in the current study (referred to as the LD-CML study). Results There subjects included 9 patients (4 men and 5 women); all were treated with dasatinib at a dose of 50 mg once daily...
October 16, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29032513/sudden-blast-phase-in-chronic-myeloid-leukemia-developed-during-nilotinib-therapy-after-major-molecular-response-was-achieved
#13
Yosuke Okada, Ken Sato, Shinichi Kobayashi, Shigeki Nagao, Kosuke Takano, Masahiro Teramoto, Noriaki Tachi, Toshikuni Kawamura, Toshikatsu Horiuchi, Shoichiro Kato, Reina Saga, Takaaki Maekawa, Takeshi Yamamura, Junichi Watanabe, Ayako Kobayashi, Fumihiko Kimura
Sudden blast phase (SBP) is a rare event in which patients with chronic myeloid leukemia (CML) in complete cytogenetic response (CCyR) rapidly progress to the blast phase. Few patients on second-generation tyrosine kinase inhibitors (2nd TKIs) have been reported to develop SBP. Here, we report a 45-year-old man diagnosed with CML in the chronic phase in April 2008 and immediately started on imatinib therapy. He achieved CCyR 12 months after starting imatinib therapy. Imatinib was followed by treatment with the 2nd TKIs nilotinib and dasatinib from January 2011 to yield a better response...
October 14, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29032022/outcomes-of-newly-diagnosed-chronic-phase-chronic-myeloid-leukemia-following-an-elective-switch-from-second-generation-tyrosine-kinase-inhibitor-to-imatinib
#14
Vamsi K Kota, Jee Hyun Kong, Martha Arellano, Fuad El Rassi, Manila Gaddh, Leonard T Heffner, Elliott F Winton, Anand P Jillella, Morgan L McLemore, H Jean Khoury
The second-generation tyrosine kinase inhibitors (TKIs) (2G-TKIs) dasatinib (DAS) and nilotinib (NIL) yield faster responses in newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML) as compared with imatinib (IM); however, long-term safety of these agents is a growing concern. We identified 20 patients with CP-CML diagnosed between August 2013 and October 2016 who initiated 2G-TKIs and were then switched after optimal response at 3 months to IM. Second-generation TKIs initiated were DAS (n = 15), NIL (n = 3), or both sequentially due to intolerance (n = 1)...
September 19, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29031704/evaluation-of-cooperative-anti-leukemic-effects-of-nilotinib-and-vildagliptin-in-ph-chronic-myeloid-leukemia
#15
Michael Willmann, Irina Sadovnik, Gregor Eisenwort, Martin Entner, Tina Bernthaler, Gabriele Stefanzl, Emir Hadzijusufovic, Daniela Berger, Harald Herrmann, Gregor Hoermann, Peter Valent, Thomas Rülicke
Chronic myeloid leukemia (CML) is a stem cell neoplasm characterized by the BCR/ABL1 oncogene. Although the disease can be kept under control using BCR/ABL1 tyrosine kinase inhibitors (TKI) in most cases, some patients relapse or have resistant disease which points to the need to identify new therapeutic targets in this malignancy. Recent data suggest that leukemic stem cell (LSC) in CML display the SC-mobilizing cell surface enzyme dipeptidyl-peptidase IV (DPPIV=CD26) in an aberrant manner. In the present study, we analyzed the effects of the DPPIV blocker vildagliptin as single agent or in combination with the BCR/ABL1 TKI imatinib or nilotinib on growth and survival of CML LSC in vitro and on LSC engraftment in an in vivo xenotransplantation NSG mouse model...
October 12, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/29030909/global-gene-expression-profiles-of-hematopoietic-stem-and-progenitor-cells-from-patients-with-chronic-myeloid-leukemia-the-effect-of-in-vitro-culture-with-or-without-imatinib
#16
Sócrates Avilés-Vázquez, Antonieta Chávez-González, Alfredo Hidalgo-Miranda, Dafne Moreno-Lorenzana, Lourdes Arriaga-Pizano, Miguel Á Sandoval-Esquivel, Manuel Ayala-Sánchez, Rafael Aguilar, Luis Alfaro-Ruiz, Hector Mayani
In this study, we determined the gene expression profiles of bone marrow-derived cell fractions, obtained from normal subjects and Chronic Myeloid Leukemia (CML) patients, that were highly enriched for hematopoietic stem (HSCs) and progenitor (HPCs) cells. Our results indicate that the profiles of CML HSCs and HPCs were closer to that of normal progenitors, whereas normal HSCs showed the most different expression profile of all. We found that the expression profiles of HSCs and HPCs from CML marrow were closer to each other than those of HSCs and HPCs from normal marrow...
October 13, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/29028530/a-pentanoic-acid-derivative-targeting-matrix-metalloproteinase-2-mmp-2-induces-apoptosis-in-a-chronic-myeloid-leukemia-cell-line
#17
Avinaba Mukherjee, Nilanjan Adhikari, Tarun Jha
Depending on our previous observations, some compounds of pentanoic acid were designed and synthesized. Characterization of the synthesized compounds was done by mass, NMR and IR spectroscopy as well as elemental analysis. Among the synthesized molecules, (2S)-5-oxo-2-[(nitrobenzene-4-yl sulfonyl) amino]-5-(pentylamino) pentanoic acid (Cpd 11) was found as a lead and potent inhibitor of matrix metalloproteinase-2 (MMP-2). Molecular modeling and enzyme inhibition studies were done to confirm the interaction or inhibitory potential of this compound...
September 27, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29027647/dasatinib-associated-reversible-demyelinating-peripheral-polyneuropathy-in-a-case-of-chronic-myeloid-leukemia
#18
Takashi Ishida, Naoyuki Akagawa, Tomomi Miyata, Naomi Tominaga, Takahiro Iizuka, Masaaki Higashihara, Takahiro Suzuki, Koji Miyazaki
Tyrosine kinase inhibitors (TKIs) are essential for the treatment of chronic myeloid leukemia (CML). Adverse effects of dasatinib have been reported; however, few reports have highlighted the association between dasatinib and demyelinating peripheral neuropathy (DPN). We report a patient with CML who developed acute onset of DPN associated with dasatinib therapy. A 46-year-old Japanese woman was treated with dasatinib for 7 months after the diagnosis of CML and she achieved a major molecular response (MMR)...
October 13, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29027641/cost-effectiveness-of-imatinib-dasatinib-and-nilotinib-as-first-line-treatment-for-chronic-phase-chronic-myeloid-leukemia-in-china
#19
Na Li, Bin Zheng, Hong-Fu Cai, Jing Yang, Xiao-Feng Luo, Li-Zhu Weng, Feng-Mei Zhan, Mao-Bai Liu
BACKGROUND AND OBJECTIVE: Tyrosine kinase inhibitors (TKIs) have obvious effects on chronic myeloid leukemia (CML), but they are expensive in China. Moreover, the overall cost of treatment of CML is high and the medical economic burden of patients with CML on the government is heavy. This study tested the cost effectiveness of imatinib, nilotinib, and dasatinib as first-line treatment in Chinese patients who were first diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP)...
October 13, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29027261/prognostic-significance-of-additional-chromosomal-abnormalities-at-the-time-of-diagnosis-in-patients-with-chronic-myeloid-leukemia-treated-with-frontline-tyrosine-kinase-inhibitors
#20
Ahmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, Farhad Ravandi, Gautam Borthakur, Courtney DiNardo, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Sherry Pierce, Guillermo Garcia-Manero, William Wierda, Srdan Verstovsek, Elias Jabbour, Jorge Cortes
Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the setting of new tyrosine kinase inhibitors (TKIs) is less well understood. Patients with CML in CP with or without ACA at diagnosis treated with frontline TKIs in prospective clinical trials were analyzed for outcomes. Among 603 patients treated, 29 (5%) had ACA. Patients with ACA included 2 of 72 (2.8%) treated with imatinib 400 mg, 9 of 207 (4...
October 13, 2017: American Journal of Hematology
keyword
keyword
15081
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"